Evaluation of Human Immunodeficiency Virus Biomarkers:Inferences From Interval and Clinical Cohort Studies

Epidemiology

Volumn 20, Issue 5, 2009, Pages 664-672

  Lau, Bryan ^a   Gange, Stephen J ^a   Kirk, Gregory D ^a   Moore, Richard D ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; HEMOGLOBIN; VIRUS RNA;

ADULT; ARTICLE; BLOOD; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; FEMALE; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOLATION AND PURIFICATION; MALE; METHODOLOGY; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; QUESTIONNAIRE; SERODIAGNOSIS;

ADULT; AIDS SERODIAGNOSIS; BIOLOGICAL MARKERS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; HEMOGLOBINS; HIV-1; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; QUESTIONNAIRES; RNA, VIRAL;

EID: 72949085285     PISSN: 10443983     EISSN: 15315487     Source Type: Journal    
DOI: 10.1097/EDE.0b013e3181a71519     Document Type: Article

References (47)

1. Lau B, Gange SJ, Moore RD. Interval and clinical cohort studies: epidemiological issues. AIDS Res Hum Retroviruses. 2007;23:769-776.
2. Vlahov D, Anthony JC, Munoz A, et al. The ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: description of methods and characteristics of participants. NIDA Res Monogr. 1991;109:75-100.
3. De Wolf F, Lange JM, Houweling JT, et al. Numbers of CD4+ cells and the levels of core antigens of and antibodies to the human immunodeficiency virus as predictors of AIDS among seropositive homosexual men. J Infect Dis. 1988;158:615-622.
4. Rezza G, Lazzarin A, Angarano G, et al. The natural history of HIV infection in intravenous drug users: risk of disease progression in a cohort of seroconverters. AIDS. 1989;3:87-90.
5. Kaslow RA, Ostrow DG, Detels R, Phair JP, Polk BF, Rinaldo CR Jr. The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol. 1987;126:310-318.
6. Barkan SE, Melnick SL, Preston-Martin S, et al. The Women's Interagency HIV Study. WIHS Collaborative Study Group. Epidemiology. 1998;9:117-125.
7. Liddell FD. The development of cohort studies in epidemiology: a review. J Clin Epidemiol. 1988;41:1217-1237.
8. van Sighem AI, van de Wiel MA, Ghani AC, et al. Mortality and progression to AIDS after starting highly active antiretroviral therapy. AIDS. 2003;17:2227-2236.
9. Portsmouth S, Stebbing J, Gill J, et al. A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma. AIDS. 2003;17:F17-F22.
10. d'Arminio MA, Lepri AC, Rezza G, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naive Patients. AIDS. 2000;14:499-507.
11. Moore RD. Understanding the clinical and economic outcomes of HIV therapy: the Johns Hopkins HIV clinical practice cohort. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;17(suppl 1):S38-S41.
12. Sudre P, Rickenbach M, Taffe P, Janin P, Volkart AC, Francioli P. Clinical epidemiology and research on HIV infection in Switzerland: the Swiss HIV Cohort Study 1988-2000. Schweiz Med Wochenschr. 2000;130:1493-1500.
13. The UK Collaborative HIV Cohort Steering Committee. The creation of a large UK-based multicentre cohort of HIV-infected individuals: The UK Collaborative HIV Cohort (UK CHIC) Study. HIV Med. 2004;5:115-124.
14. Hooshyar D, Napravnik S, Miller WC, Eron JJ Jr. Effect of hepatitis C coinfection on discontinuation and modification of initial HAART in primary HIV care. AIDS. 2006;20:575-583.
15. Kitahata MM, Rodriguez B, Haubrich R, et al. Cohort profile: the Centers for AIDS Research Network of Integrated Clinical Systems. Int J Epidemiol. 2008;37:948-955.
16. National Institutes of Health. Centers for AIDS Research. [National Institutes of Health]. 2008. Available at: .
17. Rodriguez B, Sethi AK, Cheruvu VK, et al. Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA. 2006;296:1498-1506.
18. Celentano DD, Galai N, Sethi AK, et al. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS. 2001;15:1707-1715.
19. Sterne JA, Hernan MA, Ledergerber B, et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet. 2005;366:378-384.
20. Griffin JT, Fraser C, Gras L, De Wolf F, Ghani AC. The effect on treatment comparisons of different measurement frequencies in human immunodeficiency virus observational databases. Am J Epidemiol. 2006;163:676-683.
21. Giorgi JV, Cheng HL, Margolick JB, et al. Quality control in the flow cytometric measurement of T-lymphocyte subsets: the multicenter AIDS cohort study experience. The Multicenter AIDS Cohort Study Group. Clin Immunol Immunopathol. 1990;55:173-186.
22. Schenker EL, Hultin LE, Bauer KD, Ferbas J, Margolick JB, Giorgi JV. Evaluation of a dual-color flow cytometry immunophenotyping panel in a multicenter quality assurance program. Cytometry. 1993;14:307-317.
23. Anastos K, Kalish LA, Hessol N, et al. The relative value of CD4 cell count and quantitative HIV-1 RNA in predicting survival in HIV-1-infected women: results of the women's interagency HIV study. AIDS. 1999;13:1717-1726.
24. Fahey JL, Taylor JM, Detels R, et al. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med. 1990;322:166-172.
25. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126:946-954.
26. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 1996;272:1167-1170.
27. Creagh-Kirk T, Doi P, Andrews E, et al. Survival experience among patients with AIDS receiving zidovudine. Follow-up of patients in a compassionate plea program. JAMA. 1988;260:3009-3015.
28. Lau B, Gange SJ, Phair JP, Riddler SA, Detels R, Margolick JB. Use of total lymphocyte count and hemoglobin concentration for monitoring progression of HIV infection. J Acquir Immune Defic Syndr. 2005;39:620-625.
29. Lundgren JD, Mocroft A, Gatell JM, et al. A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: results from the EuroSIDA study. J Infect Dis. 2002;185:178-187.
30. Moore RD, Keruly JC, Chaisson RE. Anemia and survival in HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;19:29-33.
31. Sullivan PS, Hanson DL, Chu SY, Jones JL, Ward JW. Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the multistate adult and adolescent spectrum of HIV disease surveillance project. Blood. 1998;91:301-308.
32. Gange SJ, Mellors JW, Lau B, et al. Longitudinal patterns of HIV type 1 RNA among individuals with late disease progression. AIDS Res Hum Retroviruses. 2001;17:1223-1229.
33. Gange SJ, Lau B, Phair J, Riddler SA, Detels R, Margolick JB. Rapid declines in total lymphocyte count and hemoglobin in HIV infection begin at CD4 lymphocyte counts that justify antiretroviral therapy. AIDS. 2003;17:119-121.
34. Lau B, Gange SJ, Phair JP, Riddler SA, Detels R, Margolick JB. Rapid declines in total lymphocyte counts and hemoglobin concentration prior to AIDS among HIV-1-infected men. AIDS. 2003;17:2035-2044.
35. de Bruijne MH, le Cessie S, Kluin-Nelemans HC, van Houwelingen HC. On the use of Cox regression in the presence of an irregularly observed time-dependent covariate. Stat Med. 2001;20:3817-3829.
36. Royston P, Altman DG. Regression using fractional polynomials of continuous covariates-parsimonious parametric modeling. J Royal Stat Soc Ser C Appl Stat. 1994;43:429-467.
37. Royston P, Ambler G, Sauerbrei W. The use of fractional polynomials to model continuous risk variables in epidemiology. Int J Epidemiol. 1999;28:964-974.
38. Sauerbrei W, Meier-Hirmer C, Benner A, Royston P. Multivariable regression model building by using fractional polynomials: Description of SAS, STATA, and R programs. Comput Stat Data Anal. 2006;50:3464-3485.
39. O'Quigley J, Xu RH, Stare J. Explained randomness in proportional hazards models. Stat Med. 2005;24:479-489.
40. O'Quigley J, Flandre P. Quantification of the prentice criteria for surrogate endpoints. Biometrics. 2006;62:297-300.
41. Efron B. The Jackknife, the Bootstrap, and Other Resampling Plans. Philadelphia: Society for Industrial and Applied Mathematics; 1982.
42. Hernan MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology. 2000;11:561-570.
43. Hernan MA, Brumback B, Robins JM. Marginal structural models to estimate the joint causal effect of nonrandomized treatments. J Am Stat Assoc. 2001;96:440-448.
44. Zeger SL, Liang KY. Longitudinal data-analysis for discrete and continuous outcomes. Biometrics. 1986;42:121-130.
45. Cole SR, Hernan MA, Robins JM, et al. Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. Am J Epidemiol. 2003;158:687-694.
46. Detels R, Munoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA. 1998;280:1497-1503.
47. 3. J Acquir Immune Defic Syndr. 2007;44:179-187.